compounds of this invention are prepared according to the procedures defined herein as method a and described in u . s . pat . nos . 5 , 081 , 131 , 5 , 079 , 247 , 4 , 728 , 663 , and 4 , 261 , 896 , which are hereby incorporated herein by reference . in addition , compounds of this invention can be prepared according to methods b and c as described in scheme i , where r 1 , r 2 , r 3 , r 4 , r 5 and q are hereinbefore defined . referring to method b , a substituted benz [ cd ] indol - 2 ( 1h )- one 1 and amine 2 where r 3 , r 5 and q are hereinbefore defined were stirred in hexamethyldisilazane for 1 to 4 hours at 120 - 130 ° c . in the presence of p - toluenesulfonic acid monohydrate to give amine 3 . alternatively , using method c , a solution of substituted benz [ cd ] indol - 2 ( h ) one 1 in tetrahydrofuran was stirred at room temperature for 1 to 4 hours in the presence of a methylene chloride solution of triethyloxonium tetrafluoroborate followed by the addition of solid na 2 co 3 and amine 2 and continued stirring at room temperature for 18 to 24 hours to afford amine 3 . reaction of amine 3 where r 5 is h , with sodium hydride in a polar solvent which includes but is not limited to n , n - dimethylformamide in the presence of potassium iodide followed by the addition of r 1 z where z is a leaving group which includes halogen , triflate , mesylate , tosylate , methyl sulfamyl , tolene sulfamyl and the like at 0 to 20 ° c . for to up 18 hours affords amine 4 . the ability of the compounds of this invention to inhibit fptase was evaluated in the standard pharmacological in vitro test procedures described below . data for representative examples is summarized in table i and table ii . enzyme test procedure : the fptase inhibition in vitro assay was performed according to the method as described by james , g . l ., brown , m . s ., and goldstein , j . l ., methods in enzymology , 1995 , 255 , 38 - 46 ; and garcia , m . a ., et al ., j . biol . chem ., 1993 , 268 , 18415 - 18420 . materials — purified fptase ( moomaw , j . f . and casey , p . j ., j . biol . chem ., 1992 , 267 , 17438 - 17443 ), purified his 6 - ras , inhibitor compounds at 10 mg / ml or 10 mm in 100 % dmso , 3 h - fpp ( 50 , 000 dpm / pmol ) amersham , tca / sds ( 6 %/ 2 %), tca ( 6 %), glass fiber filters ( 0 . 22 - 0 . 45 m ), vacuum manifold or 96 well filtration plates . methods — 1 . dilute fptase inhibitors from stock solutions to 2 . 5 × in 2 . 5 % dmso , 10 mm dtt , 0 . 5 % octyl - b - glucoside . 2 . solution # 1 is added to fptase reaction in a volume of 20 ml . 3 . standard reaction mix , 50 ml , contains 50 mm tris ( 7 . 5 ), 10 mm zncl 2 , 3 mm mgcl 2 , 20 mm kcl , 5 mm dtt , 0 . 2 % octyl - b - glucoside , 1 % dmso , 40 mm his 6 - ras , 10 ng fptase , and various concentrations of fptase inhibitors . 4 . incubate for 30 - 90 min at 25 ° c . 5 . stop reactions with tca / sds ( 6 %/ 2 %), hold at 4 ° c . for 45 - 60 min . 6 . filter by manifold or 96 well plate , wash filter 3 - 5 × with tca ( 6 %). 7 . add scintillant to filters , measure 3 h - fpp incorporation into ras protein . analysis of results — percent inhibition by test compounds is determined by the following : cell - based test procedure : the tumor inhibition in vitro assay was performed according to method as described by p . skehan , r . storeng , d . scudiero , a . monks , j . mcmohan , d . vistica , j . warren , h . bokesh , s . kenney , and m . r . boyd , j . natl . cancer instit ., 1990 , 82 ( 13 ), 1107 - 1112 ; l . v . rubinstein , r . h . shoemaker , k . d . paull , r . m . simon , s . tosini , p . skehan , d . a . scudiero , a . monks , and m . r . boyd , j . natl . cancer instit ., 1990 , 82 ( 13 ), 1113 - 1118 ; a . monks , et al ., j . natl . cancer instit ., 1991 , 83 , 757 - 766 ; m . r . boyd and k . d . paull , drug development res ., 1995 , 34 , 91 - 109 ; and s . p . fricker and r . g . buckley , anticancer research , 1996 , 16 , 3755 - 3760 . materials — cell lines : human tumor cell lines dld - 1 and lovo ; ras - transformed rat fibroblast cell lines , rat - h - ras and rat - k - ras ( growth inhibited by standard fptase inhibitors ), and the parent cell line rat - 2 ( resistant to standard fptase inhibitors ). cell media : rpmi 1640 ( or dmem medium and mccoy &# 39 ; s medium ) with 10 % fetal bovine serum supplemented with l - glutamine and pennicilin / streptomycin . compounds : supplied usually as a 10 mm stock in 100 % dmso . normal saline : 150 mm nacl trichloroacetic acid ( tca ): 50 % ( w / v ) in water . sulforhodamine ( srb ): 0 . 4 % ( w / v ) in 1 % acetic acid . tris base : 10 mm in water . methods — cells are plated at 2000 cells per well , per 200 μl media , and allowed to adhere overnight at 37 ° c . at 24 h post plating , compounds are added directly at a volume of 0 . 5 μl . compound is first diluted in dmso to generate concentrations of compound or reference standard of : 1 , 5 , 10 and 25 μm . dilutions can be made in an identical 96 well plate so that compounds can be added using a multichannel micropipettor set at 0 . 5 μl . the cells are then incubated for four days after which the media is removed using a 12 well manifold by first tipping the plate forward at a 45 degree angle and then inserting the manifold in an upright orientation to prevent the tips of the manifold from disturbing cells at the bottom of the plate . 200 μl of normal saline is then added to each well using an 8 well multichannel pipettor , followed by the careful addition of 50 μl of 50 % tca . the plates are then incubated for 2 h at 4 ° c ., after which the supernatant is removed using the same technique as above and the plates washed twice with 200 μl water . the plates are then air dried and 50 μl of srb stock solution is carefully added so that the entire bottom of each well is covered . this again can be used using an 8 well multichannel pipettor . the srb is incubated with fixed cells for 15 min at room temperature , after which the srb is removed with the manifold as described above and the plates washed twice with 350 μl of 1 % acetic acid per well each time . the plates are then air dried after which the bound srb is released from protein by the addition of 200 μl of tris base . resolubilizing the srb is aided by placing the plates on a rotator for 15 - 30 min . the absorbence of each well is determined at 550 or 562 nm using a microtiter plate reader . analysis of results — each compound or dilution thereof is performed in triplicate . outliers are identified by visual inspection of the data . each plate should have a control ( vehicle only ). a standard curve is constructed by plotting the concentration of compound against the average absorbance calculated at that concentration . a curve is plotted and the concentration at which the curve passes through the 50 % absorbance mark seen in the control well is the ic 50 calculated for that compound . based on the results of these standard pharmacological test procedures , the compounds of this invention are useful as agents for treating , inhibiting or controlling ras - associated diseases by inhibiting farnesyl - protein transferase enzyme , when administered in amounts ranging from about 10 to about 200 mg / kg of body weight per day . a preferred regimen for optimum results would be from about mg to about 100 mg / kg of body weight per day and such dosage units are employed that a total of from about 100 mg to about 1000 mg of the active compound for a subject of about 70 kg of body weight are administered in a 24 hour period . the dosage regimen for treating mammals may be adjusted to provide the optimum therapeutic response . for example , several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation . a decidedly practical advantage is that these active compounds may be administered in any convenient manner such as by the oral , intravenous , intramuscular or subcutaneous routes . the active compounds may be orally administered , for example , with an inert diluent or with an assimilable edible carrier , or they may be enclosed in hard or soft shell gelatin capsules , or they may be compressed into tablets or they may be incorporated directly with the food of the diet . for oral therapeutic administration , these active compounds may be incorporated with excipients and used in the form of ingestible tablets , buccal tablets , troches , capsules , elixirs , suspensions , syrups , wafers and the like . such compositions and preparations should contain at least 0 . 1 % of active compound . the percentage of the compositions and preparations may , of course , be varied and may conveniently be between about 2 % to about 60 % of the weight of the unit . the amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained . preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 10 and 1000 mg of active compound . the tablets , troches , pills , capsules and the like may also contain the following : a binder such as gum tragacanth , acacia , corn starch or gelatin ; excipients such as dicalcium phosphate ; a disintegrating agent such as corn starch , potato starch , alginic acid and the like ; a lubricant such as magnesium stearate ; and a sweetening agent such as sucrose , lactose , or saccharin may be added or a flavoring agnet such as peppermint , oil of wintergreen or cherry flavoring . when the dosage unit form is a capsule , it may contain , in addition to materials of the above type , a liquid carrier . various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit . for instance , tablets , pills or capsules may be coated with shellac , sugar or both . a syrup or elixir may contain the active compound , sucrose , as a sweetening agent , methyl and propylparabens as preservatives , a dye and flavoring such as cherry or orange flavor . of course , any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non - toxic in the amounts used . in addition , these active compounds may be incorporated into sustained - release preparations and formulations . these active compounds may also be administered parenterally or intraperitoneally . solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose . dispersions can also be prepared in glycerol , liquid polyethylene glycols , and mixtures therof in oils . under ordinary conditions of storage and use , these preparations contain a preservative to prevent the growth or microorganisms . the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions . in all cases , the form must be sterile and must be fluid to the extent that easy syringability exists . it must be stable under the conditions of manufacture and starage and must be prepared against the contaminating action of microorganisms such as bacteria and fungi . the carrier can be a solvent or dispersion medium containing , for example , water , ethanol , polyol ( e . g ., glycerol , propylene glycol and liquid poly - ethylene glycol ), suitable mixtures thereof , and vegetable oils . the following examples are representative compounds of this invention which are useful in inhibiting fptase . the compounds of this invention were prepared by the procedures of method a , known in the art , and described in u . s . pat . nos . 5 , 081 , 131 , 5 , 079 , 247 , 4 , 728 , 663 , and 4 , 261 , 896 , or according to the procedures of examples 20 - 22 ( methods b and c ). the product of the example was prepared using the procedure of method a and additionally prepared using the procedure of method b as described in example 21 and the procedure of method c as described in example 23 . the product of the example was prepared using the procedure of method a and additionally prepared using the procedure of method b as described in example 21 and the procedure of method c as described in example 23 . method 1 . following the procedure of examples 3 - 16 , 18 , 19 , from patents listed above . method 2 . synthesis from product of example 21 : to a stirred suspension of nah ( 60 % in mineral oil , washed with hexane and dried in vacuum ; 60 mg , 1 . 5 mmol ) in dmf ( 3 . 5 ml ), the compound from example 21 ( n -[ 3 -( 1h - imidazol - 1 - yl )- propyl ]- 6 - iodo - benz [ cd ] indol - 2 - amine ; 300 mg , 0 . 75 mmol ) was added at 0 °. the resulting mixture was stirred for 30 min at 0 ° and ki ( 20 mg , 0 . 12 mmol ) and 4 - chlorobenzyl chloride ( 145 mg , 0 . 9 mmol ) were added at the same temperature . the reaction mixture was warmed up to 20 ° during 30 min and stirred for an additional 40 min at the same temperature . water ( 10 ml ) was added and the mixture was extracted with etoac ( 40 ml ). the organic solution was washed with water ( 2 × 15 ml ) and brine ( 2 × 15 ml ) and dried over mgso 4 . filtration and evaporation provided the crude amidine . crystallization from etoac - hexane gave 270 mg ( 68 %) of a yellow solid which was characterized as [ 1 -( 4 - chloro - benzyl )- 6 - iodo - 1h - benzo [ cd ] indol - 2 - ylidene ]-( 3 - imidazol - 1 - yl - propyl )- amine : mp 146 - 1480 ; nmr ( cdcl 3 ) δ 2 . 23 ( m , 2h ), 3 . 76 ( t , j = 6 . 8 , 2h ), 4 . 16 ( t , j = 7 . 4 , 2h ), 5 . 11 ( s , 2h ), 6 . 40 ( d , j = 8 . 47 , 1h ), 6 . 85 ( s , 1h ), 7 . 03 ( s , 1h ), 7 . 26 ( m , 4h ), 7 . 39 ( s , 1h ), 7 . 70 ( m , 1h ), 8 . 83 ( m , 2h ), 8 . 88 ( d , j = 9 . 2 , 1h ). ms m / z 527 and 529 (( m + h calcd . for c 24 h 20 clin 4 526 and 528 . method a . following example 17 or method a . in example 2 , from patents listed above . method b . 6 - iodo - 1h - benzo [ cd ] indol - 2 - one ( 1 . 1 g , 3 . 73 mmol ), 1 -( 3 - aminopropyl )- imidazole ( 1 . 2 g , 9 . 6 mmol ) and p - toluenesulfonic acid monohydrate ( 0 . 1 g , 0 , 52 mmol ) were stirred in hexamethyldisilazane ( 5 ml ) for 2 h at 130 °. the reaction mixture was cooled down to 25 ° and water ( 40 ml ) was added . the resulting mixture was extracted with etoac ( 2 × 40 ml ). the combined organic solution was washed with water ( 20 ml ), and brine ( 2 × 20 ml ), and dried over mgso 4 . filtration and evaporation provided the crude amidine . crystallization from etoac - ether gave 1 . 57 g ( 80 %) of an orange colored solid which was characterized as n -[ 3 -( 1h - imidazol - 1 - yl )- propyl ]- 6 - iodo - benz [ cd ] indol - 2 - amine : mp 185 - 188 °; nmr ( cdcl 3 ) δ 2 . 30 ( m , 2h ), 3 . 64 ( t , j = 7 . 2 , 2h ), 4 . 18 ( t , j = 7 . 9 , 2h ), 6 . 90 ( d , j = 8 . 1 , 1h ), 7 . 04 ( m , 2h ), 7 . 60 ( s , 1h ), 7 . 67 ( m , 1h ), 7 . 84 ( m , 2h ), 8 . 05 ( d , j = 7 . 6 , 1h ); ms m / z 403 ( m + h calcd . for c 17 h 16 in 4 403 ). the product of the example was additionally prepared using the procedures of method c as described in example 23 . the product of the example was prepared using the procedures of method a . the product of the example was also prepared using the procedures of method b as described in example 21 . 6 - iodo - 1h - benzo [ cd ] indol - 2 - one ( 0 . 2 g , 0 . 68 mmol ), benzylamine hydrochloride ( 0 . 195 g , 1 . 36 mmol ) and p - toluenesulfonic acid monohydrate ( 0 . 01 g , 0 . 052 mmol ) were stirred in hexamethyldisilazane ( 0 . 45 ml ) for 3 h at 130 °. workup as before provided the crude product . crystallization from etoac - ether gave 0 . 172 g ( 66 %) of a dark yellow solid : mp 160 - 163 °; nmr ( cdcl 3 ) δ 4 . 90 ( s , 2h ), 6 . 99 ( d , j = 7 . 3 , 1h ), 7 . 36 ( m , 3h ), 7 . 46 ( m , 2h ), 7 . 62 ( m , 1h ), 7 . 78 ( m , 1h ), 7 . 87 ( m , 2h ). ms ( ei ) m / z 385 ( m + h calcd . for c 18 h 14 in 2 385 ). the product of the example was additionally prepared using the procedures of method c as described in example 23 . the product of the example was prepared using the procedures of method a . the product of the example was also prepared using the procedures of method b as described in example 21 . method c . to a stirred solution of 1h - benzo [ cd ] indol - 2 - one ( 0 . 15 g , 0 . 89 mmol ) in thf ( 1ml ), a 1 . 0 m solution of triethyloxonium tetraflouroborate in ch 2 cl 2 ( lml , 1 . 0 mmol ) was added at 25 ° and the resulting mixture was stirred for 3 h at the same temperature . solid na 2 co 3 ( 0 . 212 g , 2 . 0 meq ) and a solution of α , α - farnesyl amine ( 0 . 22 g , 1 . 0 mmol ) in thf ( 1 ml ) were added at 25 ° and the reaction mixture was stirred for 18 h at the same temperature . ethyl acetate ( 30 ml ) was added and the mixture was washed with water ( 2 × 10 ml and dried over mgso 4 . filtration and evaporation provided the crude product . chromatography on silica gel , eluting with etoac - hexane ( 1 : 1 ), gave 0 . 27 g ( 61 %) of a yellow oil which was identified as ( 1h - benzo [ cd ] indol - 2 - ylidene )-[( e , e )- 3 , 7 , 11 - trimethyl - 2 , 6 , 10 - dodecatrien - 1 - yl ]- amine : nmr ( cdcl 3 ) δ 1 . 59 ( s , 3h ), 1 . 60 ( s , 3h ), 1 . 68 ( d , j = 0 . 4 , 3h ), 1 . 76 ( s , 3h ), 1 . 93 - 2 . 20 ( m , 8h ), 4 . 34 ( d , j = 6 . 7 , 2h ), 4 . 96 - 5 . 04 ( m , 2h ), 5 . 48 ( m , 1h ), 6 . 96 - 8 . 12 ( m , 7h ). ms ( ei ) m / z 373 ( m + h calcd . for c 26 h 33 n 2 373 ).
the invention is a method of treating , inhibiting or controlling a ras - associated disease by inhibiting farnesyl - protein transferase enzyme , treating ras oncogene - dependent tumors , which include cancers of pancreas , breast , lung , colon , epidermis , prostate , bladder , thyroid , myelodysplastic tumors and myeloid leukemia ; controlling metastasis , suppressing angiogenesis , inducing apoptosis , and in treating ras - associated proliferative diseases other than cancer , such as restenosis , neuro - fibromatosis , endometriosis , and psoriasis , in a mammal in need thereof , which comprises administering to said mammal an effective amount of a compound of formula i : or a pharmaceutically acceptable salt thereof , wherein r 1 , r 2 , r 3 , r 4 , r 5 , q , a , and b are defined in the specification .